Bessemer Group Inc. Buys 171 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bessemer Group Inc. lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,025 shares of the medical equipment provider’s stock after purchasing an additional 171 shares during the period. Bessemer Group Inc.’s holdings in Zimmer Biomet were worth $320,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $39,000. OFI Invest Asset Management bought a new position in Zimmer Biomet during the 4th quarter valued at approximately $40,000. SRS Capital Advisors Inc. lifted its holdings in Zimmer Biomet by 146.9% in the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 285 shares during the period. Finally, Atala Financial Inc bought a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $51,000. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ZBH shares. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. BTIG Research reissued a “buy” rating on shares of Zimmer Biomet in a research report on Monday. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Down 4.7 %

Shares of Zimmer Biomet stock opened at $97.23 on Wednesday. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.19 and a 1-year high of $124.32. The company’s fifty day simple moving average is $106.07 and its 200-day simple moving average is $106.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $19.35 billion, a PE ratio of 21.85, a P/E/G ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm earned $2.20 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.99%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.